AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8252786 — intervention group
Group type: COMPARATOR
Intervention: Occlusion plus placebo
Number of subjects: 48
Study 8252786 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus occlusion vs Calcipotriol alone
Number of subjects: 48
Study 3493465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity TENS at 100 Hz for 30 min
Number of subjects: 11
Study 3493465 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 11
Study 31837209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (tVDD)
Number of subjects: 84
Study 31837209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pVDD)
Number of subjects: 84
Study 31837209 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin D deficient (nVDD)
Number of subjects: 84
Study 29650205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 44
Study 29650205 — intervention group
Group type: COMPARATOR
Intervention: Saline solution gargling
Number of subjects: 44
Study 27986077 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support with weekly home-visits
Number of subjects: 640
Study 27986077 — intervention group
Group type: COMPARATOR
Intervention: First-line ART regimens according to the National Treatment Guidelines (Control)
Number of subjects: 640
Study 24326237 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based behavioral management training (BMT)
Number of subjects: 127
Study 22443163 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stay ventilation tubes
Number of subjects: 376
Study 22443163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with short-stay ventilation tubes
Number of subjects: 376
Study 22443163 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 376
Study 22443163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 376
Study 20872115 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal high frequency thermotherapy (EHFT) combined with Chinese medicine (CM)
Number of subjects: 66
Study 20872115 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine (CM) only
Number of subjects: 66
Study 18827047 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Contact (PC)
Number of subjects: 0
Study 18827047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Technology (IT)
Number of subjects: 0
Study 18827047 — intervention group
Group type: COMPARATOR
Intervention: Self-directed usual care (SD)
Number of subjects: 0
Study 15635110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (80 mg of atorvastatin orally per day)
Number of subjects: 502
Study 15635110 — intervention group
Group type: COMPARATOR
Intervention: Moderate treatment (40 mg of pravastatin orally per day)
Number of subjects: 502
Study 14658375 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 tennis ball
Number of subjects: 16
Study 14658375 — intervention group
Group type: COMPARATOR
Intervention: Regular size tennis ball
Number of subjects: 16
Study 10405544 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfinger smears
Number of subjects: 69
Study 8543970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCNU
Number of subjects: 311
Study 8543970 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial cisplatin
Number of subjects: 311
Study 2135030 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous PCA with oxymorphone
Number of subjects: 120
Study 2135030 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous PCA with morphine
Number of subjects: 120
Study 2135030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA with oxymorphone
Number of subjects: 120
Study 2135030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA with morphine
Number of subjects: 120
Study 365313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (800-1200 mg/m2 iv q 3 weeks)
Number of subjects: 27
Study 365313 — intervention group
Group type: COMPARATOR
Intervention: Combination of Adriamycin (30-50 mg/m2 iv Day 1), 5-Fluorouracil (400-500 mg/m2 iv Day 1, 8), and Cyclophosphamide (150-200 mg/m2 po Day 3-6)
Number of subjects: 27
Study 365313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 27
Study 365313 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 27
Study 30901428 — intervention group
Group type: EXPERIMENTAL
Intervention: adaptive CBT
Number of subjects: 92
Study 30901428 — intervention group
Group type: EXPERIMENTAL
Intervention: non-adaptive CBT
Number of subjects: 92
Study 30901428 — intervention group
Group type: EXPERIMENTAL
Intervention: adaptive simulator
Number of subjects: 92
Study 30901428 — intervention group
Group type: EXPERIMENTAL
Intervention: non-adaptive simulator
Number of subjects: 92
Study 30901428 — intervention group
Group type: EXPERIMENTAL
Intervention: lecture
Number of subjects: 92
Study 29133942 — intervention group
Group type: EXPERIMENTAL
Intervention: ns1 gene (100 µg)
Number of subjects: 18
Study 29133942 — intervention group
Group type: EXPERIMENTAL
Intervention: vp3 gene (100 µg)
Number of subjects: 18
Study 29133942 — intervention group
Group type: EXPERIMENTAL
Intervention: ns1 + vp3 gene combination (100 µg each)
Number of subjects: 18
Study 29133942 — intervention group
Group type: COMPARATOR
Intervention: Negative control (base values before therapy)
Number of subjects: 18
Study 29133942 — intervention group
Group type: COMPARATOR
Intervention: Positive control (after complete remission)
Number of subjects: 18
Study 25384968 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonal injection of 0.05 mL of bevacizumab
Number of subjects: 10
Study 25384968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique injection of 0.05 mL of bevacizumab
Number of subjects: 10
Study 24070635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions (specific types not detailed)
Number of subjects: 261
Study 24070635 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 261
Study 21440505 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months NADT plus radiotherapy
Number of subjects: 802
Study 21440505 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months NADT plus radiotherapy
Number of subjects: 802
Study 21440505 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 802
Study 18270842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 50
Study 18270842 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar age distribution)
Number of subjects: 50
Study 17069269 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural Care Model for Multiple Sclerosis
Number of subjects: 173
Study 17069269 — intervention group
Group type: COMPARATOR
Intervention: Traditional care as usual
Number of subjects: 173
Study 12879082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Number of subjects: 18
Study 12879082 — intervention group
Group type: COMPARATOR
Intervention: Caseinate
Number of subjects: 18
Study 11083409 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0
Study 11083409 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blocker treatment
Number of subjects: 0
Study 11083409 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study 9118031 — intervention group
Group type: EXPERIMENTAL
Intervention: HCVAb positive groups (I and IV)
Number of subjects: 202
Study 9118031 — intervention group
Group type: COMPARATOR
Intervention: Group II (HBsAg[+], HCVAb[‐])
Number of subjects: 202
Study 9118031 — intervention group
Group type: COMPARATOR
Intervention: HCVAb negative groups (II and III)
Number of subjects: 202
Study 9118031 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-related HCC
Number of subjects: 202
Study 1731289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulindac for 48 hours
Number of subjects: 36
Study 1731289 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin for 48 hours
Number of subjects: 36
Study 2862318 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipuncture skin test with excretory-secretory (ES) toxoplasma antigen
Number of subjects: 414
Study 2862318 — intervention group
Group type: COMPARATOR
Intervention: Indirect fluorescent antibody (IFA) test
Number of subjects: 414
Study 30872538 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 15
Study 30872538 — intervention group
Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 15
Study 30872538 — intervention group
Group type: COMPARATOR
Intervention: Screening programs
Number of subjects: 15
Study 29020818 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile Justice Anger Management (JJAM) Treatment for Girls
Number of subjects: 57
Study 27634090 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration during bipedal stance on foam with eyes closed
Number of subjects: 20
Study 27634090 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration during bipedal stance on BOSU
Number of subjects: 20
Study 24955858 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h on-call shift (OCD)
Number of subjects: 30
Study 22001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined implementation intention
Number of subjects: 580
Study 22001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate implementation intentions
Number of subjects: 580
Study 22001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Target strategies
Number of subjects: 580
Study 22001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory strategies
Number of subjects: 580
Study 22001024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 580
Study 19967530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6-g/kg dose of ethanol
Number of subjects: 32
Study 19967530 — intervention group
Group type: EXPERIMENTAL
Intervention: Future event simulation
Number of subjects: 32
Study 19967530 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 32
Study 17009633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Group 1 (first dose)
Number of subjects: 106
Study 17009633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Group 2 (second dose)
Number of subjects: 106
Study 17009633 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 106
Study 14558587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg/kg injected over 2 minutes with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Number of subjects: 45
Study 14558587 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo solution with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Number of subjects: 45
Study 14558587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol with propofol.
Number of subjects: 45
Study 11140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Diskhaler
Number of subjects: 12
Study 11140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Diskus
Number of subjects: 12
Study 11140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Metered-Dose Inhaler (MDI)
Number of subjects: 12
Study 11140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via all devices
Number of subjects: 12
Study 9547133 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg single dose, followed by 150 mg three times a day for 4 weeks)
Number of subjects: 15
Study 9547133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single blind)
Number of subjects: 15
Study 8436154 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG 0.5 microgram.kg‐1 x min‐1
Number of subjects: 6
Study 8436154 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study 3787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.16 ppm
Number of subjects: 24
Study 3787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.14 ppm
Number of subjects: 24
Study 3787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.12 ppm
Number of subjects: 24
Study 3787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.10 ppm
Number of subjects: 24
Study 3787644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.08 ppm
Number of subjects: 24
Study 3787644 — intervention group
Group type: COMPARATOR
Intervention: Ozone exposure at 0.00 ppm (control)
Number of subjects: 24
Study 30281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light cystoscopy with hexaminolevulinate (BLC-H)
Number of subjects: 1375
Study 30281893 — intervention group
Group type: COMPARATOR
Intervention: White-light cystoscopy (WLC)
Number of subjects: 1375
Study 30281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cytology
Number of subjects: 1375
Study 30281893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade/WHO grade 1 disease
Number of subjects: 1375
Study 30281893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade/WHO grade 3 disease
Number of subjects: 1375
Study 28763434 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol (5 mL/kg infusion for 15 minutes)
Number of subjects: 39
Study 28763434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (5 mL/kg infusion for 15 minutes)
Number of subjects: 39
Study 28763434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 39
Study 28763434 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 39
Study 28763434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 26830981 — intervention group
Group type: EXPERIMENTAL
Intervention: URSA Complex
Number of subjects: 0
Study 26830981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24433929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal neuropsychological intervention (attention retraining, learning strategies, psychoeducation, psychological support, homework assignments) conducted once a week in 60-minute sessions for thirteen consecutive weeks
Number of subjects: 56
Study 22492768 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed descriptions, CC presented first
Number of subjects: 309
Study 22492768 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed descriptions, IC presented first
Number of subjects: 309
Study 22492768 — intervention group
Group type: COMPARATOR
Intervention: Brief descriptions, CC presented first
Number of subjects: 309
Study 22492768 — intervention group
Group type: COMPARATOR
Intervention: Brief descriptions, IC presented first
Number of subjects: 309
Study 20802056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with ropivacaine (2.5 mg · kg(‐1) ropivacaine 0.75%)
Number of subjects: 40
Study 20802056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with ropivacaine
Number of subjects: 40
Study 20802056 — intervention group
Group type: COMPARATOR
Intervention: Placebo TAP block (saline)
Number of subjects: 40
Study 19166424 — intervention group
Group type: EXPERIMENTAL
Intervention: RLF (20 mg rabeprazole, 500 mg levofloxacin, 200 mg furazolidone once daily for 10 days)
Number of subjects: 60
Study 19166424 — intervention group
Group type: EXPERIMENTAL
Intervention: RBDF (20 mg rabeprazole, 120 mg bismuth subcitrate, 100 mg doxycycline, 200 mg furazolidone twice daily for 10 days)
Number of subjects: 60
Study 17374039 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine 25 mg QID
Number of subjects: 127
Study 17374039 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 10 mg TID
Number of subjects: 127
Study 17374039 — intervention group
Group type: EXPERIMENTAL
Intervention: topiramate 25 mg QID
Number of subjects: 127
Study 17374039 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg TID
Number of subjects: 127
Study 17374039 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study 12771706 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 months for 1 year)
Number of subjects: 106
Study 12771706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 months for 1 year)
Number of subjects: 106
Study 12771706 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 106
Study 12771706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 10698384 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone, 50 microg/kg
Number of subjects: 20
Study 10698384 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine, 0.03 microg/kg/min
Number of subjects: 20
Study 9331129 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with paclitaxel 175 to 225 mg/m2 and carboplatin (target AUC of 7.5) followed by G-CSF priming for 5 days before treatment.
Number of subjects: 35
Study 9331129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality treatment (induction followed by concurrent thoracic radiation and chemotherapy).
Number of subjects: 35
Study 9331129 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with escalated paclitaxel dose of 225 mg/m2 on days 1 and 22 after initial patients accrued.
Number of subjects: 35
Study 9331129 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiation and chemotherapy.
Number of subjects: 35
Study 9331129 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic radiation and chemotherapy with esophageal exposure.
Number of subjects: 35
Study 8164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with prednimustine (60 mg daily)
Number of subjects: 78
Study 8164452 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment with prednimustine (200 mg daily for five days every two weeks)
Number of subjects: 78
Study 8164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with prednimustine
Number of subjects: 78
Study 8164452 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment with prednimustine
Number of subjects: 78
Study 8164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 78
Study 3746457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine
Number of subjects: 4
Study 3746457 — intervention group
Group type: EXPERIMENTAL
Intervention: D-methionine
Number of subjects: 4
Study 3746457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine-dl-sulfoxide
Number of subjects: 4
Study 31725899 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm trial in rare cancer disease using propensity score matching to construct an external control from RWD
Number of subjects: 0
Study 31725899 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial in children with multiple sclerosis borrowing strength from past trials using a Bayesian meta-analytic approach
Number of subjects: 0
Study 30405294 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg PO)
Number of subjects: 87
Study 30405294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 26186880 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth‐containing quadruple therapy (BCQT)
Number of subjects: 149
Study 26186880 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth‐containing levofloxacin‐based triple therapy (CBS‐LAL)
Number of subjects: 149
Study 26186880 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth‐containing clarithromycin‐based triple therapy (CBS‐LAC)
Number of subjects: 149
Study 24446953 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 5 mg/day
Number of subjects: 400
Study 24446953 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 20 mg/day
Number of subjects: 400
Study 24446953 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 400
Study 24446953 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 400
Study 22397900 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy (RSC)
Number of subjects: 447
Study 22397900 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 447
Study 20888992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone (25 mg/m2 cabazitaxel intravenously over 1 h every 3 weeks)
Number of subjects: 755
Study 20888992 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (12 mg/m2 mitoxantrone intravenously over 15-30 min)
Number of subjects: 755
Study 18377099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000-7,000 IU per day)
Number of subjects: 0
Study 18377099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of Vitamin D supplementation (55-70 ng per mL)
Number of subjects: 0
Study 18377099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological doses of Vitamin D (2,000 IU per kg per day for three days)
Number of subjects: 0
Study 15824291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin sodium, 175 IU/kg every 24 hours
Number of subjects: 505
Study 15824291 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin sodium, 200 IU/kg every 24 hours
Number of subjects: 505
Study 12598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and propofol (Group M-P)
Number of subjects: 26
Study 12598270 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone (Group M)
Number of subjects: 26
Study 10226868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 or 8 mg once daily
Number of subjects: 707
Study 10226868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard 1-8 mg once daily
Number of subjects: 707
Study 10226868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 10226868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 707
Study 10226868 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin standard
Number of subjects: 707
Study 8657211 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units over one hour)
Number of subjects: 310